Sandbox cerebral palsy: Difference between revisions

Jump to navigation Jump to search
Aditya Ganti (talk | contribs)
Aditya Ganti (talk | contribs)
 
(13 intermediate revisions by the same user not shown)
Line 21: Line 21:
**Mucosal defects along with dilated and tortuous vessels in dieulafoy lesion put them at risk for rupture because of necrosis of the arterial wall from exposure to gastric acid.
**Mucosal defects along with dilated and tortuous vessels in dieulafoy lesion put them at risk for rupture because of necrosis of the arterial wall from exposure to gastric acid.
{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | | A01 | | | | | |A01=NSAIDS}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | A01 | | | | | |A01=Inflammatory Bowel Disease}}
{{familytree | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | A01 | | | | | |A01=Inhibits cycloxygenase pathway}}
{{familytree | | | | | | | | | | | | | |,|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|.| | }}
{{familytree | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | B02 |B01=Crohn's Disease|B02=Ulcerative colitis}}
{{familytree | | | | | |,|-|-|-|-|^|-|-|-|-|-|.| | | }}
{{familytree | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | |!| }}
{{familytree | | | | | B01 | | | | | | | | | B02 |B01=COX-1|B02=COX-2}}
{{familytree | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | | | |!|}}
{{familytree | | | | | |!| | | | | | | | | | |!| | | }}
{{familytree | | | | | | | Z01 | | | | | | | | | | Z02 | | | | | | | | |!| |Z01=Based on Region involved|Z02=Based on Severity}}
{{familytree | |,|-|-|-|+|-|-|-|.| | | |,|-|-|^|-|-|-|.| }}
{{familytree | | | |,|-|-|-|+|-|-|-|.| | | |,|-|-|-|+|-|-|-|.| | | | | |!| | }}
{{familytree | C01 | | C02 | | C03 | | C04 | | | | | C05 | |C01=Reduced<br>mucosal blood flow|C02=Reduced<br> mucosal and<br> bicarbonate secreation|C03=Impaired<br>platelet aggregation|C04=Reduced<br>angiogenesis|C05=Increased<br>leucocyte adherence|}}
{{familytree | | | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | | | |!| |C01=Ileocolic Crohn's disease|C02=Crohn's ileitis|C03=Crohn's colitis|C04=Stricturing disease|C05=Penetrating disease|C06=Inflammatory disease}}
{{familytree | |!| | | |!| | | |!| | | |!| | | | | | |!| | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|.| | }}
{{familytree | |`|-|-|-|^|-|-|-|+|-|-|-|^|-|-|-|-|-|-|'| | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | Z01 | | | | | | | | Z02 | |Z01=Based on Region involved|Z02=Based on Severity}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | |,|-|-|-|^|-|.| | | |,|-|-|-|+|-|-|-|v|-|-|-|.| }}
{{familytree | | | | | | | | | E01 | | | | | | | | | | | | |E01=Impaired defence<br>Impaired healing}}
{{familytree | | | | | | | | | | | | | | | | | | | C01 | | | | C02 | | C03 | | C04 | | C05 | | C06 | C01=Distal UC|C02=Proximal UC|C03=Mild|C04=Moderate|C05=Severe|C06=Flumiant|}}  
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | F01 | | | | | | | | | | | | |F01=Mucosal Injury}}
{{familytree/end}}
{{familytree/end}}


{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | | A01 | | | | | |A01=A01}}
{{familytree | | | | | | | | | | | | | | | A01 | | | | | | | | | | | |A01=A01}}
{{familytree | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | A02 | | | | | |A02=A02}}
{{familytree | | | | | | | | | | | | | | | B01 | | | | | | | | | | | |B01=B01}}
{{familytree | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | A02 | | | | | |A02=A02}}
{{familytree | | | | | | |,|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|.| | | | | | | }}
{{familytree | | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | |!| | | | | | | }}
{{familytree | | | | | |,|-|-|-|-|^|-|-|-|-|-|.| | | }}
{{familytree | | | | | | C01 | | | | | | | | | | | | | | | C02 | | | | | | |C01=C01|C02=C02}}
{{familytree | | | | | B01 | | | | | | | | | B02 |B01=B01|B02=B02}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | |!| | | | | | | | | | |!| | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | D01 | | | | | | |D01=D01}}
{{familytree | | | | | C01 | | | | | | | | | C02 | | | C01=C01|C02=C02}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | |!| | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | E01 | | | | | | |E01=E01}}
{{familytree | | | | | | | | | | | | | | | | D01 | | | |D01=D01}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | |!| | | | | |}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | F01 | | | | | | |F01=F01}}
{{familytree | | | | | | | | | | | | | | | | E01 | | | | |E01=E01 }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | G01 | | | | | | |G01=G01}}  
{{familytree | | | | | | | | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | |}}
{{familytree | | | | | | | | | | B01 | | | | B02 | | | | B03 | | |B01=B01|B02=B02|B03=B03}}
{{familytree | | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|-|.|}}
{{familytree | | | | | | | | | | |!| | | | | |!| | | | | |!| | | | }}
{{familytree | | | | | | | | | | | | | | | | | H01 | | | | | | | | | | | H02 | |H01=H01|H02=H02}}
{{familytree | | | | | | | | | | |!| | | | | |!| | | | | |!| | | | }}
{{familytree | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| }}
{{familytree | | | | | | | | | | C01 | | | | C02 | | | | C03 | | |C01=C01|C02=C02|C03=C03}}  
{{familytree | | | | | | | | | | | | | | | | | I01 | | | | | | | | | | | I02 | | |I01=I01|I02=I02}}
{{familytree | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | J01 | | | | | | | | | | | | | | |J01=J01}}
{{familytree/end}}
{{familytree/end}}
==Pathogenesis of Crohn's disease==
==Pathogenesis of Crohn's disease==
*Genetic component
*Genetic component
Line 105: Line 107:
*Stress signals are perceived by the central nervous system (CNS), triggering the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary axis.
*Stress signals are perceived by the central nervous system (CNS), triggering the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary axis.
*Neuroendocrine mediators released in response to stress not only modulate secretory, absorptive, and barrier functions in the gut but also increase the gut permeability.
*Neuroendocrine mediators released in response to stress not only modulate secretory, absorptive, and barrier functions in the gut but also increase the gut permeability.
*Factors involved in the effects of stress on gut permeability include
*Stress increases gut permeability along with other factors which inlude
**Corticotropin-releasing factor
**Corticotropin-releasing factor
**Autonomic nervous system
**Autonomic nervous system
**Enteric nervous system
**Enteric nervous system
===Microbial Component===
===Microbial Component===
The possible mechanisms for a bacterial etiology in the development of CD include:
The possible mechanisms for a bacterial etiology in the development of CD include:
Line 116: Line 119:
*Alterations to the intestinal immune response
*Alterations to the intestinal immune response


{| class="wikitable"
{| border="1" cellpadding="5" cellspacing="0" align="center" |class="wikitable"
!Infectious Pathogens Implicated in Crohn’s Disease
! style="background:#efefef;" |Infectious Pathogens Implicated in Crohn’s Disease
|-
|-
|Escherichia coli
|
Listeria monocytogenes
*Escherichia coli<br>
 
*Listeria monocytogenes<br>
Yersinia enterocolitica
*Yersinia enterocolitica<br>
 
*Mycobacterium avium subspecies paratuberculosis<br>
Mycobacterium avium subspecies paratuberculosis
*Measles virus
 
Measles virus
|}
|}


Line 137: Line 138:
** Activation resulted in secretion of tumor necrosis factor-alpha (TNF-alpha) and subsequent epithelial changes.
** Activation resulted in secretion of tumor necrosis factor-alpha (TNF-alpha) and subsequent epithelial changes.
*'''<u>Cytokine response</u>''':
*'''<u>Cytokine response</u>''':
**A T-cell mediated immune response has been identified in the mucosa of CD, in contrast to UC, and is postulated to be the primary precipitating event.
**The primary precipitating event in Crohn's disease is T-cell mediated immune response.
**The ensuing production of inflammatory cytokines can cause ulceration and increased intestinal permeability.
**Activated T cells are responsible for the release of cytokines.
**Animal models confirm the generally held consideration that CD is primarily a T-helper 1-(Th1) dominant condition.
**The production of inflammatory cytokines results in ulceration and increased intestinal permeability.
**In murine models, disease induced by a Th1 over-expression results in lesions histologically compatible with CD (including granulomas), while a T-helper 2- (Th2) mediated response results in lesions more closely resembling ulcerative colitis (including a lack of granulomas).
**The characteristic granulomatous lesion seen in Crohn’s disease is evidence of a cell-mediated immune response.
**As mentioned, the characteristic granulomatous lesion seen in Crohn’s disease is evidence of a cell-mediated immune response.
**The early lesions of Crohn's disease are characterized by elevations in interleukin-4 (IL-4) and decrease in IFN-gamma, a pattern more consistent with an overactive Th2 immune response.
**In human studies, while chronic CD appears to involve primarily an overactive Th1 response characteristic of a cell-mediated phenomenon, some researchers have determined divergent cytokine patterns at different stages of the disease.
**Chronic lesions are associated with high levels of interleukin-2 (IL-2), interferon gamma (IFN-gamma), TNF-alpha, and interleukin-12 and -18 (IL-12 and IL-18) consistent with an Th1 immune response.
**Chronic lesions are associated with high levels of interleukin-2 (IL-2), interferon gamma (IFN-gamma),87 TNF-alpha, and interleukin-12 and -18 (IL-12 and IL-18).
**Tumor necrosis factor appears to play a significant role in the pathogenesis of CD.
**Desreumaux et al, however, found a distinctly different cytokine pattern in the early CD.  
***TNF-alpha induces expression of adhesion factors that allow for inflammatory cells to infiltrate and activates macrophages to promote release of other pro-inflammatory mediators such as IFN-gamma.
**By examining ileal biopsy specimens of 17 patients compared to 11 controls, the researchers determined that early lesions were characterized by elevations in interleukin-4 (IL-4) and decrease in IFN-gamma, a pattern more consistent with an overactive Th2 immune response.
***Neutralization of TNF resulted in significant decrease in inflammation.
**Other researchers have found, at least in animal models, the opposite may be true. In a mouse model of ileitis (a CD-like enteritis), researchers found elevated Th2 cytokines, including IL-4, during the chronic phase of the disease.
***TNF-alpha concentrations in the stool can be used to monitor disease activity in both CD and UC.
**IL-18 is up-regulated in Crohn’s disease. Although typically considered to be an activator of Th1 responses, IL-18 has actually been shown to be a pleiotropic cytokine capable of mediating both Th1 and Th2 responses, providing more potential evidence for divergent cytokine patterns in the pathogenesis of CD.
==Oxidative stress==
**Another study examined human colonic tissue samples and found IL-16 protein levels elevated in CD patients but not UC patients.
*Oxidative stress also plays a significant role in the pathogenesis of Crohn's disease.
**The same study found an anti-human IL-16 antibody could suppress colonic injury in a murine model of Crohn’s-like experimental colitis.
 
**Pro-inflammatory cytokines are normally kept in check by immunosuppressive cytokines such as transforming growth factor beta (TGFbeta).
*Endogenous antioxidants such as superoxide dismutase (SOD), glutathione, and catalase normally counteract oxidative stress in the intestinal mucosa.
**It is believed the transcription factor T-bet is integral to controlling the balance between pro and anti-inflammatory cytokines.
*However, during the times of inflammation the demand for these antioxidants is increased resulting in an imbalance between oxidants and antioxidants, with subsequent mucosal damage.
**T-bet is elaborated by Th1 cells, but not Th2 cells. IFN-gamma is enhanced by T-bet. Neurath et al examined Tbet activity in lamina propria T-cells of patients with CD as well as in animal models.
*Oxidative DNA damage can be measured from the amount of 8-hydroxy-deoxy-guanosine (8-OhdG) present in blood.
**The researchers discovered T-bet over-expression in the lamina propria T-cell nucleus in patients with CD, but not UC or controls.
*Levels of 8-OhdG are higher in patients with Crohn's disease.
**In the animal models, T-bet overexpression was consistent with Th1-mediated colitis (animal model of CD), while a T-bet deficiency was protective.
*Oxidative stress can also activate nuclear factor-kappaB (NF-kappaB) gene leading to release of TNF-alpha and interleukins involved in inflammation.
**Tumor necrosis factor appears to play a significant role in the pathogenesis of CD. Mucosal biopsies of children with IBD compared to controls found a significantly greater number of TNF-alpha-secreting cells in patients with CD compared to those with UC or non-specific bowel inflammation.91 A significant difference between mild-to-moderate and severe disease was also noted for the CD subgroup, with severe disease demonstrating a significantly greater percentage of TNF-secreting cells. In animal models of Crohn’s ileitis, neutralization of TNF resulted in significant decrease in inflammation.
 
**Indeed, suppression of TNF-alpha is the primary mechanism of action of the monoclonal antibody category of CD medications (see Conventional Treatments below).
== Other factors responsible for Pathogenesis of Crohn's disease ==
**TNF-alpha contributes to gut inflammation in several ways. It induces expression of adhesion factors that allow for inflammatory cells to infiltrate and activates macrophages to promote release of other pro-inflammatory mediators such as IFN-gamma.
 
**TNF-alpha concentrations in the stool can be used to monitor disease activity in both CD and UC.
===== Platelet Abnormalities =====
** Braegger et al compared 13 children with
* Increased platelet count is a common feature of active Crohn’s disease and contributes to the increased incidence of thromboembolism seen in both CD and UC.
* In addition to increased platelet count, CD is characterized by increased platelet activation in the mesenteric vessels.
* Although platelet function has historically been considered to involve primarily blood clotting, there is considerable evidence for platelet involvement in inflammation.  
* Platelets from inflammatory bowel-diseased tissues have been found to express a number of inflammatory mediators, including CD40 L, a substance similar to tumor necrosis factor that directs platelets toward inflammation instead of aggregation.
* A sequence of events has been postulated in which platelets trigger chemokine-mediated adhesion of white blood cells to the endothelium, causing leukocyte migration and subsequent focal inflammatory lesions.
 
===== Mitochondrial Dysfunction =====
* TNF alpha enhances mitochondrial NF-kappa B expression, down-regulating mitochondrial RNA expression.
* Resulting in impaired oxidative phosphorylation,with abnormalities in complexes III and IV.
 
===== Elevated Homocysteine =====
* Vitamin B12 is essential for the metabolism of homo-cysteine to cysteine, taurine, sulfate, and glutathione.  
* Conditions that result in vit-B6 deficiency can lead to an increased levels of homo-cysteine levels.
 
* Higher levels of homo-cysteine levels are associated with hypocoagulation states and subsequent thrombosis.
* Therefore Crohn's patients are at risk for thrombo-embolism due to high homo-cysteine levels.
 
==The Lactulose-Mannitol Test for Small Intestinal Hyperpermeability==
*Patient is made to swallows a solution of 5 g mannitol and 5 g lactulose.
*Urine sample is collected for six hours.
*Assay for total lactulose and mannitol
**< 14% mannitol = carbohydrate malabsorption
**>1% lactulose = disaccharide hyperpermeability
{{familytree/start}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | A01 | | | | | | | |A01=A01 }}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | | | |,|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|.| | | |}}
{{familytree | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | B02 | | | |B01=B01|B02=B02}}
{{familytree | | | | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|.| | | |!| | | | | }}
{{familytree | | | | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | C07 | | |!| | | | |C01=C01|C02=C02|C03=C03|C04=C04|C05=C05|C06=C06|C07=C07}}
{{familytree | | | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | | | |}}
{{familytree | | | | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | | C07 | | |!| | | | |C01=C01|C02=C02|C03=C03|C04=C04|C05=C05|C06=C06|C07=C07}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|-|^|-|-|-|-|.|}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | B01 | | | | | | | | B02 |B01=B01|B02=B02}}
{{familytree/end}}
 
 
{{familytree/start}}
{{familytree | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | |B01=B01|B02=B02}}
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | | }}
{{familytree | | | | C01 | | | | | | | | | | C04 | | | | | | | | | | C07 | | | | | | | |C01=C01|C04=C04|C07=C07}}
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | C01 | | | | | | | | | | C04 | | | | | | | | | | C07 | | | | | | | |C01=C01|C04=C04|C07=C07}}
{{familytree/end}}
 
 
{{familytree/start}}
{{familytree | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | |B01=B01}}
{{familytree | | | | | | | | | | | | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | C03 | | C04 | | C05 | | | | |C03=C03|C04=C04|C05=C05|}}
{{familytree | | | | | | | | | | | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | | | | | C03 | | C04 | | C05 | | | | | | | | | | | |C03=C03|C04=C04|C05=C05|}}
{{familytree/end}}

Latest revision as of 23:49, 3 February 2018

Pathophysiology

Mucosal barrier

  • The gastric mucosa is protected from the acidic environment by mucus, bicarbonate, prostaglandins, and blood flow.
  • This mucosal barrier consists of three protective components which include:
    • Layer of epithelial cells lining.
    • Layer of mucus, secreted by surface epithelial cells and Foveolar cells.
    • Bicarbonate ions, secreted by the surface epithelial cells.

Mechanism of Action

  • The insoluble mucus forms a protective gel-like coating over the entire surface of the gastric mucosa.
  • The mucus protects the gastric mucosa from autodigestion by e.g. pepsin and from erosion by acids and other caustic materials that are ingested.
  • The bicarbonate ions act to neutralize harsh acids.
  • If the balance of gastric acid secretion and mucosal defenses is disrupted, acid interacts with the epithelium to cause damage

Pathogenesis

  • Regardless of etiology, if the balance of gastric acid secretion and mucosal defenses is disrupted, acid interacts with the epithelium to cause damage.
    • Helicobacter pylori disrupts the mucosal barrier and causes inflammation of the mucosa of the stomach and duodenum.
    • As the ulcer progresses beyond the mucosa to the submucosa the inflammation causes weakening and necrosis of arterial walls, leading to pseudoaneurysm formation followed by rupture and hemorrhage.
    • NSAIDs inhibit cyclooxygenase, leading to impaired mucosal defenses by decreasing mucosal prostaglandin synthesis.
    • During stress, there is acid hypersecretion; therefore, the breakdown of mucosal defenses leads to injury of the mucosa and subsequent bleeding.
    • Mucosal defects along with dilated and tortuous vessels in dieulafoy lesion put them at risk for rupture because of necrosis of the arterial wall from exposure to gastric acid.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory Bowel Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crohn's Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
Ulcerative colitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on Region involved
 
 
 
 
 
 
 
 
 
Based on Severity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ileocolic Crohn's disease
 
Crohn's ileitis
 
Crohn's colitis
 
Stricturing disease
 
Penetrating disease
 
Inflammatory disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on Region involved
 
 
 
 
 
 
 
Based on Severity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distal UC
 
 
 
Proximal UC
 
Mild
 
Moderate
 
Severe
 
Flumiant


 
 
 
 
 
 
 
 
 
 
 
 
 
 
A01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H01
 
 
 
 
 
 
 
 
 
 
H02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I01
 
 
 
 
 
 
 
 
 
 
I02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J01
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Pathogenesis of Crohn's disease

  • Genetic component
  • Stress and environmental component
  • Microbial component
  • Inflammatory component

Genetic Component

Genes involved

  • NOD2/CARD15 gene
  • OCTN1 gene
  • DLG5 gene
  • TLR4 gene
Genes Chromosome Function Mutation
NOD2/CARD15 16 16q12.1 Encodes a scaffolding protein important for maintaining epithelial integrity Disrupts normal epithelial integrity
OCTN1 05 5q31 Ecodes an ion channel Alters the function of cation transporters and cell-to-cell signaling
DLG5 10 10q22.3 Interact additively with the NOD2/CARD15 gene Iincrease susceptibility to CD along with CARD15
TLR4 09 9q33.1 Lipopolysaccharide signaling, bacterial recognition, and subsequent immune response Altered immune response to pathogens and a subsequent increase in inflammation.

Stress and Environmental Component

  • Stress signals are perceived by the central nervous system (CNS), triggering the hypothalamic-pituitary-adrenal axis and the sympathetic-adrenal-medullary axis.
  • Neuroendocrine mediators released in response to stress not only modulate secretory, absorptive, and barrier functions in the gut but also increase the gut permeability.
  • Stress increases gut permeability along with other factors which inlude
    • Corticotropin-releasing factor
    • Autonomic nervous system
    • Enteric nervous system

Microbial Component

The possible mechanisms for a bacterial etiology in the development of CD include:

  • Initial immune response to a specific pathogen resulting in intestinal infection
  • Alterations in normal bacterial flora of the intestinal tract
  • Defective mucosal barrier and overwhelming exposure to resident bacteria and their antigens and endotoxins
  • Alterations to the intestinal immune response
Infectious Pathogens Implicated in Crohn’s Disease
  • Escherichia coli
  • Listeria monocytogenes
  • Yersinia enterocolitica
  • Mycobacterium avium subspecies paratuberculosis
  • Measles virus

Immune Component

  • Altered immune response:
    • An abnormal antibody response to an unspecified bacterial antigen is mainly responsible for inflammation in Crohn's disease.
    • The inflammatory response is believed to be triggered when elimination of specified microbial antigen was unsuccessful leading to altered immune response
    • Dysregulation of normal mucosal immune response results in failure of phagocytosis leading to antigen persistence.
    • Antigen persistance leads to antibodies production against all the normal gut flora.
    • Activation resulted in secretion of tumor necrosis factor-alpha (TNF-alpha) and subsequent epithelial changes.
  • Cytokine response:
    • The primary precipitating event in Crohn's disease is T-cell mediated immune response.
    • Activated T cells are responsible for the release of cytokines.
    • The production of inflammatory cytokines results in ulceration and increased intestinal permeability.
    • The characteristic granulomatous lesion seen in Crohn’s disease is evidence of a cell-mediated immune response.
    • The early lesions of Crohn's disease are characterized by elevations in interleukin-4 (IL-4) and decrease in IFN-gamma, a pattern more consistent with an overactive Th2 immune response.
    • Chronic lesions are associated with high levels of interleukin-2 (IL-2), interferon gamma (IFN-gamma), TNF-alpha, and interleukin-12 and -18 (IL-12 and IL-18) consistent with an Th1 immune response.
    • Tumor necrosis factor appears to play a significant role in the pathogenesis of CD.
      • TNF-alpha induces expression of adhesion factors that allow for inflammatory cells to infiltrate and activates macrophages to promote release of other pro-inflammatory mediators such as IFN-gamma.
      • Neutralization of TNF resulted in significant decrease in inflammation.
      • TNF-alpha concentrations in the stool can be used to monitor disease activity in both CD and UC.

Oxidative stress

  • Oxidative stress also plays a significant role in the pathogenesis of Crohn's disease.
  • Endogenous antioxidants such as superoxide dismutase (SOD), glutathione, and catalase normally counteract oxidative stress in the intestinal mucosa.
  • However, during the times of inflammation the demand for these antioxidants is increased resulting in an imbalance between oxidants and antioxidants, with subsequent mucosal damage.
  • Oxidative DNA damage can be measured from the amount of 8-hydroxy-deoxy-guanosine (8-OhdG) present in blood.
  • Levels of 8-OhdG are higher in patients with Crohn's disease.
  • Oxidative stress can also activate nuclear factor-kappaB (NF-kappaB) gene leading to release of TNF-alpha and interleukins involved in inflammation.

Other factors responsible for Pathogenesis of Crohn's disease

Platelet Abnormalities
  • Increased platelet count is a common feature of active Crohn’s disease and contributes to the increased incidence of thromboembolism seen in both CD and UC.
  • In addition to increased platelet count, CD is characterized by increased platelet activation in the mesenteric vessels.
  • Although platelet function has historically been considered to involve primarily blood clotting, there is considerable evidence for platelet involvement in inflammation.
  • Platelets from inflammatory bowel-diseased tissues have been found to express a number of inflammatory mediators, including CD40 L, a substance similar to tumor necrosis factor that directs platelets toward inflammation instead of aggregation.
  • A sequence of events has been postulated in which platelets trigger chemokine-mediated adhesion of white blood cells to the endothelium, causing leukocyte migration and subsequent focal inflammatory lesions.
Mitochondrial Dysfunction
  • TNF alpha enhances mitochondrial NF-kappa B expression, down-regulating mitochondrial RNA expression.
  • Resulting in impaired oxidative phosphorylation,with abnormalities in complexes III and IV.
Elevated Homocysteine
  • Vitamin B12 is essential for the metabolism of homo-cysteine to cysteine, taurine, sulfate, and glutathione.
  • Conditions that result in vit-B6 deficiency can lead to an increased levels of homo-cysteine levels.
  • Higher levels of homo-cysteine levels are associated with hypocoagulation states and subsequent thrombosis.
  • Therefore Crohn's patients are at risk for thrombo-embolism due to high homo-cysteine levels.

The Lactulose-Mannitol Test for Small Intestinal Hyperpermeability

  • Patient is made to swallows a solution of 5 g mannitol and 5 g lactulose.
  • Urine sample is collected for six hours.
  • Assay for total lactulose and mannitol
    • < 14% mannitol = carbohydrate malabsorption
    • >1% lactulose = disaccharide hyperpermeability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B01
 
 
 
 
 
 
 
 
 
 
 
 
 
B02
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C01
 
C02
 
C03
 
C04
 
C05
 
C06
 
C07
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C01
 
C02
 
C03
 
C04
 
C05
 
C06
 
C07
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B01
 
 
 
 
 
 
 
B02


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C01
 
 
 
 
 
 
 
 
 
C04
 
 
 
 
 
 
 
 
 
C07
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C01
 
 
 
 
 
 
 
 
 
C04
 
 
 
 
 
 
 
 
 
C07
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C03
 
C04
 
C05
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C03
 
C04
 
C05